Table 2 Comparison of clinical variables between all phase-locked and non-phase-locked groups in schizophrenia.

From: Application of evoked response audiometry for specifying aberrant gamma oscillations in schizophrenia

 

All phase-lockeda

Non-phase-lockedb

P value

46-Hz AM-FM ASSR

Number of cases

24

14

 

Gender (male/female)

12/12

8/6

0.61

Age, y, mean ± SD

44.0 ± 11.1

51.4 ± 9.1

0.03

Illness duration, y

20.3 ± 11.8

27.1 ± 11.4

0.73

GAF

35.9 ± 15.5

31.1 ± 17.2

0.12

BPRS, four-dimensional model

  

Thinking disturbancec

5.0 ± 3.3

8.1 ± 4.8

0.20

Withdrawal/retardationd

4.5 ± 3.4

5.9 ± 4.9

0.27

Hostile/suspiciousness

2.6 ± 2.9

3.0 ± 2.9

0.06

Anxious/depression

2.7 ± 2.3

3.2 ± 2.4

0.07

Antipsychoticse, mg/day

700 ± 99

1388 ± 336

0.06

Classification of antipsychoticsf

12/12

3/11

0.06

40-Hz AM ASSR

Number of cases

28

10

 

Gender (male/female)

16/12

4/6

0.83

Age, y, mean ± SD

45.0 ± 11.3

51.5 ± 8.1

0.05

Illness duration, y

21.3 ± 12.3

27.0 ± 10.7

0.69

GAF

35.0 ± 16.1

31.6 ± 16.4

0.14

BPRS, four-dimensional model

  

Thinking disturbance

5.4 ± 3.2

8.3 ± 5.8

0.11

Withdrawal/retardation

4.5 ± 3.3

6.7 ± 5.3

0.10

Hostile/suspiciousness

2.8 ± 3.1

2.6 ± 2.3

0.12

Anxiety/depression

2.9 ± 2.3

2.8 ± 2.3

0.18

Antipsychotics, mg/day

901 ± 183

1099 ± 223

0.75

Classification of antipsychotics

13/15

2/8

0.05

  1. aThe group of patients who had the phase-locked responses in all three measurements (patients without non-phase-locked responses).
  2. bThe group of patients who had non-phase-locked responses, at least one in three measurements (patients with non-phase-locked responses).
  3. cPositive symptoms.
  4. dNegative symptoms.
  5. eChlorpromazine equivalent dose.
  6. fNew generation antipsychotics only/Conventional antipsychotics or combination (new generation and conventional antipsychotics).
Back to article page